vimarsana.com
Home
Live Updates
Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma : comparemela.com
Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma
Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.
Related Keywords
United Kingdom ,
Manchester ,
Ibrutinib Imbruvica ,
Ann Tivey ,
International Prognostic Score Index ,
University Of Manchester ,
Prognostic Score Index ,
Ibrutinib ,
Mantle Cell Lymphoma ,
Cmcl ,
Rituximab ,
comparemela.com © 2020. All Rights Reserved.